COVID-19 updates

COVID-19: Our response and path forward

Updated on October 27, 2022

Bristol Myers Squibb recognizes COVID-19 has created unique challenges for each of us. We are focused on ensuring the continued supply of our medicines to our patients and protecting the health, wellbeing and safety of our workforce. We are also supporting research efforts to accelerate the development, manufacturing, and delivery of diagnostics and treatments for COVID-19, and contributing to relief efforts across the globe. 
We will take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to patients who depend on us. We will continue to operate with compassion, diligence and patience to meet the needs of all of our stakeholders as the environment in which we operate continues to evolve.

More on our response

Patient Support Program

(toll free U.S. only)

Clinical Trial Investigators
Clinical Trial Investigators

Latest update on July 31, 2020

Patient Advocacy Groups

Patient Advocacy Groups

Frequently asked questions

How is Bristol Myers Squibb contributing to COVID-19 research efforts and helping to identify and accelerate the delivery of diagnostics and treatments for COVID-19?

How is the COVID-19 pandemic affecting the supply of Bristol Myers Squibb medicines?

What patient support programs are available for patients during this time? 

Where can patients go for questions about COVID-19 treatment and Bristol Myers Squibb medicines?

How is COVID-19 affecting Bristol Myers Squibb clinical trials and ongoing research efforts?

How is Bristol Myers Squibb protecting healthcare providers and patients?

What is Bristol Myers Squibb’s approach to returning its broader workforce to sites and the field? 

How do I reach the media team at Bristol Myers Squibb?

Where can I find more information about how the pharmaceutical industry’s response to COVID-19?

Where can I go for more information about COVID-19?

* This requirement is subject to state and local law restrictions and may not be applicable to employees working in certain jurisdictions. This requirement is also subject to discussions with collective bargaining representatives in the U.S.

** Subject to local law, vaccine availability, discussions with collective bargaining representatives, consultations with employee representatives and works councils.

Last Updated On: October 27, 2022